Compare Amer Sports Inc (AS) vs BioNTech SE - ADR (BNTX) Price & Performance

Amer Sports (AS) trades at $33.03, down 8.68% in the past 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings of $0.38 per share, beating estimates, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by Arc'teryx and Salomon. Valuation ratios include a P/E of 42.3 and P/S of 2.8. Net income margin stands at 6.5% for 2025.

The outlook is positive due to consistent earnings beats and raised guidance, but high valuation and technical bearishness pose risks. Analyst consensus is strongly bullish with a $58.67 price target, suggesting significant upside. Key risks include reliance on brand momentum and market volatility. Investors should weigh strong fundamentals against current technical weakness.

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.